New hope for scleroderma patients: tofacitinib vs methotrexate in skin thickening battle
NCT ID NCT07472166
First seen Apr 17, 2026 · Last updated May 22, 2026 · Updated 5 times
Summary
This study tested whether tofacitinib, a drug that calms the immune system, works better than methotrexate at reducing skin hardening in people with a severe form of scleroderma. 34 adults with early-stage diffuse scleroderma took part. Researchers measured skin thickness using a standard scoring system and tracked side effects over 24 weeks.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SCLERODERMA, SYSTEMIC are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Department of Rheumatology, Bangabandhu Sheikh Mujib Medical University (BSMMU)
Dhaka, 1000, Bangladesh
Conditions
Explore the condition pages connected to this study.